Evofem Biosciences, Inc.
EVFM
$0.01
$0.002.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 277.69% | 12.05% | -286.61% | 131.48% | -28.41% |
| Total Depreciation and Amortization | -100.85% | -12.59% | -49.25% | 4.72% | -13.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 183.24% | 6.35% | 108.19% | -309.23% | 190.42% |
| Change in Net Operating Assets | -433.28% | 172.13% | -133.18% | 314.19% | -492.08% |
| Cash from Operations | -90.77% | 111.51% | -621.25% | 123.26% | -424.62% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -111.20% | 200.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 96.49% | -23.91% | 90.96% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -13.93% | 1.61% | -83.70% | 49.44% | -1.91% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -18.85% | -109.53% | 1,996.30% | -105.46% | 147.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -384.78% | 125.48% | -198.10% | 1,836.84% | -36.67% |